标题:Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
作者:Zhao C.; Dong H.; Xu Q.; Zhang Y.
作者机构:[Zhao, C] Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong U 更多
通讯作者:Zhang, Y(zhangyingjie@sdu.edu.cn)
通讯作者地址:[Zhang, Y] Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong 更多
来源:Expert Opinion on Therapeutic Patents
出版年:2020
DOI:10.1080/13543776.2020.1725470
关键词:cancer; Histone deacetylases; hybrids; inhibitors
摘要:Introduction: Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer. Area covered: This review covers recent efforts in the synthesis and applications of inhibitors and hybrid inhibitors targeting HDAC from 2017 to 2019. Expert opinion: HDACs are important epigenetic targets and HDAC inhibitors have become important biologically active compounds for the treatment of cancers. Among the recent patents available, most of them place emphasis on HDAC selective inhibitors and multitarget HDAC inhibitors. Although great accomplishments have been achieved in developing HDAC selective inhibitors, there is still an urgent need for discovery of novel HDAC inhibitors with new zinc-binding groups avoiding the unfavorable pharmacokinetics profiles of hydroxamic acid. Apart from cancer therapy, HDAC inhibitors have recently been considered as a new strategy in treating other human diseases, such as alcohol use disorder (AUD), neurological disorders, age-related diseases, and so forth. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
收录类别:SCOPUS
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079074667&doi=10.1080%2f13543776.2020.1725470&partnerID=40&md5=d49a8d8104eb013416bfab97103ab32c
TOP